Semaglutide: What It Is and How It's Used in the Philippines

Quick read: Semaglutide is a pure GLP-1 receptor agonist, the compound behind Ozempic and Wegovy. It's the most studied GLP-1 agonist for weight loss, with trial data showing 10-15% body weight reduction over 68 weeks. In the PH community, it's often the entry point for first-time GLP-1 users due to lower cost and extensive safety data. Common dosing is 0.5-2.4mg weekly.

What it is

Semaglutide is a synthetic analog of human GLP-1 (glucagon-like peptide-1), a hormone produced in the gut that regulates appetite and blood sugar. It works by binding to GLP-1 receptors in the brain (specifically the hypothalamus), pancreas, and GI tract.

The mechanism is threefold: it slows gastric emptying (you feel fuller longer), increases insulin secretion in response to food, and reduces glucagon release (which lowers blood sugar). The net effect is powerful appetite suppression and improved glycemic control.

Structurally, semaglutide is modified at two positions to resist degradation by the enzyme DPP-4, and it includes a fatty acid side chain that allows it to bind to albumin in the blood. This extends its half-life to roughly 7 days, enabling once-weekly dosing.

Novo Nordisk developed semaglutide and brought it to market as Ozempic (for type 2 diabetes, approved 2017) and Wegovy (for obesity, approved 2021). The STEP-1 trial showed participants on 2.4mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group (Wilding 2021).

In the PH peptide landscape, semaglutide sits between tirzepatide and retatrutide in terms of potency and cost. It's the most accessible option for someone dipping their toes into GLP-1 therapy. It's also commonly added to retatrutide protocols for users who plateau, though that's an advanced stacking approach.

What it's used for

Primary use: weight loss in people with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27 with hypertension, dyslipidemia, or sleep apnea). This is the FDA-approved Wegovy indication.

Secondary use: type 2 diabetes management. Semaglutide lowers HbA1c by 1.5-2% on average in T2D patients. Some people in the PH community run it preventatively if they're prediabetic or have strong family history of diabetes.

Tertiary use: body recomposition in people who are already lean but want to cut the last layer of stubborn fat. This is off-label and less common, but some users at 18-22% body fat run low doses (0.5-1mg weekly) to tighten up without extreme dieting.

Semaglutide is also studied for cardiovascular risk reduction. The SELECT trial (2023) showed that semaglutide reduced major adverse cardiovascular events by 20% in people with established cardiovascular disease, independent of weight loss.

What it's NOT used for: muscle gain, performance enhancement, or athletic recovery. The appetite suppression makes it nearly impossible to eat in a surplus. Some bodybuilders use it during contest prep cuts, but that's a niche application.

Realistic expectations: 10-15% body weight loss over 6-12 months is the typical outcome in community logs. A 90kg person can expect to reach 76-81kg with adherence. Results depend heavily on protein intake and resistance training. Without lifting, a significant portion of weight loss will be muscle.

Typical protocols

The FDA-approved Wegovy titration schedule:

• Month 1: 0.25mg weekly
• Month 2: 0.5mg weekly
• Month 3: 1.0mg weekly
• Month 4: 1.7mg weekly
• Month 5+: 2.4mg weekly (maintenance dose)

This slow ramp minimizes GI side effects. Most users in the PH community follow a similar pattern, though some accelerate the titration if sides are tolerable.

Common community dosing:

• Conservative: 0.5-1.0mg weekly
• Moderate: 1.0-1.7mg weekly
• Aggressive: 2.4mg weekly (trial max dose)

Some users micro-dose by splitting the weekly dose into two pins (e.g., 1mg becomes 0.5mg twice weekly). This smooths the appetite curve and can reduce nausea, though it's not the studied protocol.

Timing: Pin on the same day each week. Time of day doesnt matter due to the 7-day half-life. Many users pin Sunday evening to align with their weekly routine.

Pin location: Subcutaneous, typically abdomen or thigh. Rotate sites to avoid lipohypertrophy or injection site reactions.

Reconstitution: Semaglutide comes as lyophilized powder. A common setup is 5mg powder + 2mL bacteriostatic water = 2.5mg/mL concentration. For a 1mg weekly dose, that's 0.4mL per pin.

Cycle length: Semaglutide is often run continuously rather than cycled. Trial data extends to 68 weeks for weight loss, and longer for diabetes management. Some users run it for 6-12 months, then taper off. Others stay on indefinitely at a low maintenance dose (0.5-1mg weekly).

What users typically report

Week 1-4 (0.25mg): Appetite suppression is mild but noticeable. Most users can still eat normally, but snacking impulses drop. Some people feel mild nausea, especially after rich meals. Energy levels are usually stable.

Week 5-8 (0.5mg): Appetite suppression becomes more pronounced. This is where weight loss starts to become consistent, usually 0.5-1kg per week. The biggest challenge is eating enough protein. Some users report feeling full after just a few bites, which makes hitting macro targets difficult.

Week 9-12 (1.0mg): The appetite suppression is strong. Food becomes less interesting. Cravings for sweets and hyperpalatable foods (lechon, halo-halo, pastries) often disappear completely. Some users describe it as "food noise" shutting off. Fatigue can become an issue if calorie intake drops too low.

Week 13-20 (1.7-2.4mg): Weight loss continues but may slow as the body adapts. The compound has done most of its work by this point. Users who push to 2.4mg often dont see a proportional increase in effect compared to 1.7mg. Some report diminishing returns.

Response variance: From community logs, about 60-70% of users respond well to semaglutide. Around 10-15% are hyper-responders who lose weight rapidly and feel strong appetite suppression even at 0.5mg. Another 15-20% are weak responders who need higher doses or see minimal benefit.

Compared to tirzepatide and retatrutide, semaglutide has the strongest pure appetite suppression. Some users describe it as too much, where eating feels like a chore rather than something they have to resist.

Common side effects

The textbook list from trials: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, injection site reactions.

Community-reported reality:

Nausea (40-60% of users): The most common side effect, especially during titration. Peaks in the first 2-3 days post-pin. Triggered by eating too much, eating too fast, or rich/fatty foods. Most users adapt within 6-8 weeks.

Constipation (25-35%): More common than diarrhea in PH logs, likely due to reduced food volume and slower GI motility. Worse if fiber intake is low and hydration is poor.

Fatigue (20-30%): Often correlates with undereating. If you're only consuming 1000-1300 calories daily because appetite is crushed, low energy is inevitable.

Acid reflux / heartburn (15-25%): Related to delayed gastric emptying. Worse when lying down after meals or eating late at night.

"Ozempic face" (anecdotal, 5-10%): Facial volume loss and sagging skin during rapid weight loss, especially in older users (40+). Not a direct drug effect, but a consequence of losing subcutaneous fat quickly without adequate collagen support.

Hair thinning (5-10%, anecdotal): Reported during rapid weight loss phases. Likely due to caloric restriction and nutrient deficiency rather than the drug itself.

Serious but rare: pancreatitis (black-box warning), medullary thyroid carcinoma (contraindicated with family history), severe hypoglycemia (mainly in T2D patients on insulin), gallbladder issues (cholelithiasis).

Compared to tirzepatide, semaglutide tends to cause slightly more nausea but less bloating. Compared to retatrutide, it's gentler overall but with stronger food aversion.

Side effect management

Nausea: Eat smaller, more frequent meals. Avoid high-fat or greasy foods for 48 hours post-pin. Ginger (tea or capsules) can help. Famotidine 20mg before bed reduces reflux-related nausea. If nausea is severe, consider splitting the weekly dose into two smaller pins or dropping back a titration step.

Constipation: Increase fiber to 25-35g daily. Psyllium husk (Metamucil) is effective. Drink 3-4 liters of water daily. Magnesium citrate 200-400mg before bed acts as a gentle laxative. If needed, use a stool softener like docusate.

Fatigue: Track your calories. Most people undereat without realizing it. Aim for at least 1500-1800 calories daily, with 1.6-2g protein per kg body weight. If fatigue persists, check thyroid (TSH, free T3, free T4) and ferritin.

Heartburn: Famotidine 20mg before bed. Dont eat within 3 hours of lying down. Elevate the head of your bed. If persistent, omeprazole 20mg daily can help, but long-term PPI use has downsides (nutrient malabsorption, bone density concerns).

Hair thinning: Ensure adequate protein, biotin (5000mcg daily), and micronutrients (zinc, iron). Consider collagen supplementation or GHK-Cu for skin/hair support during weight loss.

"Ozempic face": This is harder to prevent. Slower weight loss (0.5kg per week instead of 1kg) may help. Resistance training and adequate protein preserve muscle mass, which supports facial structure. Some users add GHK-Cu or dermal fillers post-weight-loss.

When to lower dose: If nausea prevents adequate protein intake for more than a week. If fatigue interferes with daily function. If GI sides dont improve after 2-3 weeks at a given dose.

When to stop: Severe abdominal pain (potential pancreatitis). Family history of medullary thyroid cancer discovered after starting. Pregnancy or trying to conceive.

Who this compound is for

Semaglutide is for people with 10+ kg to lose who have plateaued on diet and training. The ideal user is someone who has been through multiple diet cycles, experiences constant hunger and food preoccupation, and needs pharmacological support to create a sustainable deficit.

It's well-suited for the Filipino corporate demographic: desk workers in BGC/Makati in their 30s-50s with central adiposity from sedentary work and eating-out culture. People who cant consistently meal prep due to work/family demands.

It's also appropriate for people with prediabetes or metabolic syndrome who want to improve insulin sensitivity and prevent progression to type 2 diabetes.

From a training perspective, semaglutide works best for people who lift regularly and prioritize protein. The appetite suppression makes it easy to lose weight, but without resistance training, a large portion of that loss will be muscle.

First-time GLP-1 users often start with semaglutide because it has the longest safety track record and is generally well-tolerated at low doses (0.5-1mg).

Realistic outcome: A 90kg person running semaglutide for 6-12 months can expect to reach 76-81kg. If they lift 3-4x weekly and hit 120-150g protein daily, most of that loss will be fat.

Who this compound is NOT for

Pregnancy, trying to conceive, or breastfeeding: Do not run semaglutide. It crosses the placenta and is excreted in breast milk.

Family history of medullary thyroid carcinoma or MEN2 syndrome: Absolute contraindication per black-box warning.

Active or recent pancreatitis: Contraindicated.

Type 1 diabetes: Semaglutide is not a replacement for insulin.

Severe gastroparesis or GI motility disorders: Semaglutide slows gastric emptying, which can worsen these conditions.

History of eating disorders: The strong appetite suppression can reinforce disordered patterns. If you have a history of anorexia, bulimia, or severe food restriction, this compound is risky.

People who refuse to lift or track protein: You'll lose weight, but much of it will be muscle. If you dont care about body composition and just want the scale number to drop, semaglutide will work. But the result is often skinny-fat.

People expecting the compound to fix everything: Semaglutide makes it easier to eat in a deficit, but it doesnt address poor sleep, chronic stress, or lack of movement. If your lifestyle is otherwise broken, the compound will only take you partway.

Healthy BMI vanity cuts: If you're already lean (15-18% body fat for men, 22-25% for women) and just want to get shredded, semaglutide is overkill. You'd be better served with a structured diet for 8-12 weeks.

PH-specific considerations

Lower-cost option vs tirzepatide and retatrutide: Semaglutide is typically the most affordable GLP-1 option in the PH sourcing landscape. This makes it the default entry point for first-time users or people running extended protocols where cost adds up.

Cold chain and climate storage: Semaglutide should be refrigerated at 2-8°C before reconstitution, and for up to 56 days after reconstitution. In PH, brownouts are a concern. If the power goes out for more than 4-6 hours, the vial may degrade. Some users store vials at a friend's place with backup power or use battery-powered mini-fridges.

For domestic travel (Manila to Cebu, Davao, provinces), use an insulated cooler with ice packs. Most airlines in PH allow medical coolers in carry-on.

PH clinic landscape: Ozempic and Wegovy are available through Makati/BGC wellness clinics, but the markup is steep. Clinic pricing often runs 3-5x the DIY sourcing route. The clinic advantage is medical oversight, regular bloodwork, and a legal prescription. The disadvantage is cost and rigid dosing protocols.

Independent sourcing is common in the PH peptide community, but verifying purity and sterility is challenging. COA (certificate of analysis) from suppliers should be reviewed, though fake COAs exist.

Diet integration with Filipino food culture: Semaglutide's appetite suppression makes it hard to finish traditional Filipino meals. Rice 3x daily becomes impossible for most users. This can create social friction at family gatherings. The workaround is to load your plate with protein (adobo, grilled fish, tinola chicken) and take just a few bites of rice for appearance.

Eating out in BGC/Makati (sisig, lechon kawali, buffets) loses its appeal. Rich, fatty foods often trigger nausea. Users gravitate toward simpler meals: grilled chicken, sinigang, steamed vegetables.

Filipino body type considerations: The "skinny-fat" phenotype is common in the PH population (low muscle mass, high visceral fat despite normal BMI). Semaglutide will reduce total body weight, but without resistance training, it can worsen the skinny-fat look by stripping subcutaneous fat while leaving little muscle underneath.

Ozempic pen extraction: Some PH users buy Ozempic pens (legally or grey-market) and extract the liquid to dose more flexibly. This requires sterile technique and carries contamination risk. Compounded semaglutide from research suppliers is more common in the DIY community.

Common stacks

Semaglutide + Tirzepatide: Some advanced users stack low-dose semaglutide (0.5-1mg weekly) with low-dose tirzepatide (5-7.5mg weekly) to hit both GLP-1 and GIP pathways. This is off-label and not studied in trials. The logic is synergistic appetite suppression, but side effect risk increases.

Semaglutide + Retatrutide: For users who plateau on retatrutide, adding semaglutide (0.5-1mg weekly) can provide a GLP-1 boost without ramping reta dose higher. This is an advanced approach and not recommended for beginners.

Semaglutide + Tesamorelin: Tesamorelin targets visceral fat via GH pathway. Stacking with semaglutide creates a dual-mechanism fat loss approach. Protocol: 1mg semaglutide weekly + 1-2mg tesamorelin daily before bed.

Semaglutide + CJC-1295 + Ipamorelin: For body recomposition rather than pure fat loss. The GH secretagogues help preserve lean mass during the caloric deficit. Protocol: 1mg semaglutide weekly + 100mcg CJC + 200mcg Ipa before bed daily.

Avoid stacking with other pure appetite suppressants unless you're intentionally trying to create extreme suppression (which increases side effect risk and makes hitting protein targets nearly impossible).

Avoid MK-677 unless the goal is to offset semaglutide's appetite suppression, which defeats the purpose.

Things to watch

Bloodwork baseline (before starting):

• Fasting glucose, HbA1c
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Liver enzymes (AST, ALT)
• Thyroid panel (TSH, free T3, free T4)
• CBC

Week 6-8 recheck:

• Fasting glucose, HbA1c (should improve)
• Lipid panel (typically improves with weight loss)
• Liver enzymes (should remain stable)

Week 12+ ongoing:

• Every 12 weeks: fasting glucose, HbA1c, lipids
• TSH every 6 months (some users report thyroid changes during prolonged GLP-1 use)
• If running high doses (2.4mg), consider checking amylase/lipase to screen for subclinical pancreatitis

Subjective metrics to track:

• Weekly weight (same day, same time, fasted)
• Waist circumference (more accurate than scale weight for visceral fat)
• Strength in the gym (if strength drops significantly, you're undereating or losing muscle)
• Hunger cues and food preoccupation (track whether "food noise" quiets down)

Red flags that mean stop immediately:

• Severe abdominal pain, especially upper abdomen radiating to the back (pancreatitis)
• Persistent vomiting for more than 24 hours
• Rapid heartbeat, chest pain, shortness of breath
• Signs of severe dehydration (dark urine, dizziness, confusion)

PH labs (Hi-Precision, MedGrocer, clinical labs in Makati/BGC) offer comprehensive metabolic panels for 2000-4000 PHP.

Coming off / cycling

Semaglutide does not require a pharmacological taper. It's not habit-forming and doesnt cause withdrawal. However, appetite will return to baseline (or above) relatively quickly after stopping.

Timeline after last pin:

• Week 1-2: Residual appetite suppression due to 7-day half-life
• Week 3-4: Appetite returns to pre-semaglutide baseline
• Week 5+: Rebound hunger is common, especially if you've been in a deficit for months

Weight regain risk: Trial data shows participants who stop semaglutide without lifestyle changes regain most of the lost weight within 12-18 months. The compound doesnt fix the habits that led to weight gain.

Strategies to minimize rebound:

• Taper dose gradually over 6-8 weeks (2.4mg → 1.7mg → 1.0mg → 0.5mg → 0.25mg → stop)
• Transition to maintenance calories rather than jumping back to old eating patterns
• Continue tracking protein and lifting to preserve muscle
• Consider a low maintenance dose (0.5mg weekly) rather than stopping completely

Cycling approach: Some users run semaglutide for 6-12 months, then cycle off for 8-12 weeks to allow GLP-1 receptors to resensitize. This is anecdotal and not studied in trials.

Long-term use: The longest trial data is 68 weeks for weight loss, and multi-year data exists for diabetes management. Some community members have been on semaglutide continuously for 2+ years. Long-term safety beyond 2-3 years is less clear.

---

Related compounds

• Tirzepatide — Dual GLP-1/GIP agonist, often the next step up from semaglutide
• Retatrutide — Triple agonist, stronger fat loss but harsher sides
• Cagrilintide — Amylin analog, sometimes combined with semaglutide (CagriSema)

Further reading

• Beginner guide to GLP-1 agonists — Start here if new to GLP-1 therapy
• Sourcing framework — How to verify purity and navigate PH sourcing
• Side effect management overview — Comprehensive GLP-1 side effect strategies

Sources

• Wilding 2021 — STEP-1 trial, semaglutide 2.4mg for obesity, 68-week data showing 14.9% weight loss
• Rubino 2022 — STEP-4 trial, weight maintenance after semaglutide discontinuation
• Davies 2021 — SUSTAIN trial series, semaglutide for type 2 diabetes
• Lincoff 2023 — SELECT trial, cardiovascular outcomes with semaglutide
• Knudsen 2010 — Pharmacokinetics and pharmacodynamics of semaglutide

---

Last updated: 2026-05-20. This page is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.